Loaʻa i nā maʻi maʻi mRNA pilikino kahi pilikia hana - a hiki i ka Peptide Analytics ke kōkua i ke kūkulu ʻana i nā kaʻina hana maikaʻi.

Pane wikiwiki

E aʻo pehea ka hana ʻana o ka n-of-1 i ka hoʻokele ʻana i ka palapala hoʻomohala maʻi mRNA pilikino i nā papahana peptide kiʻekiʻe-a me nā huahana modular…

ʻO ke kumu hoʻohālike n-o-1 a me kāna mau ʻano like ʻole ma Peptide R&ʻO D

Nā lawelawe Pono nā lāʻau lapaʻau mRNA pilikino i hoʻokahi pahu hana i kēlā me kēia maʻi, no kēlā me kēia pōʻaiapuni lapaʻau. ʻO kēlā me kēia pūʻulu e pili ana i ka genomic sequencing, helu helu neoantigen prioritization, mRNA hana, hoʻokumu ʻana i ka lipid nanoparticle, a hoʻokuʻu i ka hoʻāʻo—nā mea a pau i loko o kahi puka lapaʻau i ana ʻia i nā pule. A 2026 ka nānā ʻana i paʻi ʻia ma BioPharma Dive ua ʻike ʻo ka hoʻolaha ʻana i ka pāʻoihana o kēia mau kano e koi ai i "mau ʻumi kaukani o nā pūʻulu pākahi,"ʻo ia ka mea i "haʻihaʻi nui i ke kumu hoʻohālike hana maʻamau."

Nā polokalamu peptide e hana ana ma waena o ka hoʻomohala ʻana i ka maʻi neoantigen, MHC-peptide tetramer panel, a i ʻole nā ​​hale waihona puke kānana kiʻekiʻe e kū nei i kahi paʻakikī like ʻole. Pono paha kahi papahana ʻike hoʻokahi i 15-30 mau kaʻina hana maʻamau i hoʻohui ʻia ma ka milligram a i ka nui-gram scale., kēlā me kēia me kona ʻano hoʻololi ponoʻī, koi hoʻomaʻemaʻe, a hoʻokuʻu kikoʻī. ʻO ka neʻe maikaʻi ʻana ma waena o nā kaʻina - me ka ʻole o ke kūkulu hou ʻana i ka ʻōnaehana analytical a me nā palapala i kēlā me kēia manawa-he ʻāpana hiki ke kuhikuhi pololei i nā mea hana mRNA e hana nei e pani..

ʻEhā mau loina hana e hoʻoponopono i kēia āpau. Loaʻa kēlā me kēia mai ka hoʻomaʻamaʻa peptide CMC i hoʻokumu ʻia a mai nā palapala hana modular e puka mai ana no ka therapeutics pilikino..

Hoʻohuihui Peptide Loaʻa i nā maʻi maʻi mRNA pilikino kahi pilikia hana - a hiki i ka Peptide Analytics ke kōkua i ke kūkulu ʻana i nā kaʻina hana maikaʻi.

Haʻawina 1: Hoʻemi ʻo Modular Production Architecture i ka Sequence-Change Risk

No ke aha ia mea. ʻO nā kaʻina hana hana monolithic-i hoʻolālā ʻia i ka hopena-a-hope a puni kahi ʻano kaʻina hoʻokahi-hiki ʻole i ka wā e hālāwai ai kahi papahana i kahi peptide paʻakikī.. I ka hoʻohui ʻana i ka SPPS, ʻO nā ʻano hana hāʻule maʻamau e pili ana i nā hemahema hoʻohui hydrophobic i nā kaʻina kaulahao lōʻihi, ka hoʻohui ʻana ma-resin i manaʻo ʻole ʻia i ka wā lōʻihi synthetic cycles, a hāʻule hāʻule i ka pae deprotection ke pale ʻole ʻia nā kūlana hoʻoneʻe hui i kēia papa kaʻina kikoʻī.. Ke monolithic ke kaʻina hana, ʻO kēlā me kēia hemahema e pono ke kūkulu hou ʻia mai ka wā ʻōpala. Ke hana modular, hiki ke hoʻokaʻawale ʻia kēlā me kēia hemahema i kahi hana ʻāpana kikoʻī a hoʻoponopono ʻia me ka hoʻopilikia ʻole i nā mea ʻē aʻe.

Pehea e hoʻokō ai. Hoʻonohonoho ka papa hana peptide synthesis modular i ka hana ʻokoʻa, nā poloka hiki ke hoʻonohonoho hou ʻia: koho ala (SPSS, LPPS, ʻāpana ʻāpana-condensation), kemika hui (nā mea hoʻāla hoʻāla, manawa pōʻai, nā hoʻomalu mahana), ka hoomaemae ana (hoʻolālā gradient RP-HPLC hoʻomākaukau, nā pae hoʻohālike hoʻohui hakina), a me ka hooponopono ana (hoʻololi kūʻē, pōʻai lyophilization, ka hoʻoheheʻe ʻana). Hāʻawi kēlā me kēia poloka i nā mea hoʻokomo i wehewehe ʻia, nā mea hoʻopuka, a me ka ʻae ʻana ʻaʻole i hilinaʻi i nā kikoʻī o nā poloka pili.

No nā kaʻina i luna 30 nā amino acids a i ʻole nā ​​pae hoʻololi he nui, ʻO Neuland 2026 Alakaʻi hoʻomohala CMC paipai ʻia i kahi ʻanuʻu ʻimi ala ala ma mua o ka hana ʻana i kekahi ala synthesis: e loiloi i ka SPPS me nā ʻāpana ʻāpana hybrid me ka hoʻohana ʻana i nā sub-sequences pōkole, me ka maʻemaʻe a me ka hua e like me ka hoʻoholo ʻana ma mua o ka hoʻohālikelike ʻana i kahi molekala kūleʻa mua.

ʻO kahi papa hana hoʻoholo koho ala kūpono:

Hiʻona kaʻina

ʻO ke ala synthesis makemake

ʻO ka pilikia nui e nānā

≤20 AA, koena maʻamau

SPSS (Fmoc)

ʻO ka hōʻiliʻili ʻana

21–35 AA, koena maʻamau

SPPS me nā mana racemization

Hoʻohui piha i kēlā me kēia pōʻai

>35 AA a i ʻole nā ​​mea paʻa disulfide lehulehu

ʻO ka ʻāpana ʻāpana huila condensation

ʻĀpana ʻāpana hale kūʻai pono

He nui ka hydrophobic

SPPS me pseudoproline dipeptides

ʻO ka hui ʻana ma ka resin

Nā kūlana i hoʻopaʻa ʻia i ka Isotope

SPPS me nā koena isotopologue i pale ʻia

ʻO Scrambling ma ke kaʻina hana

Pehea ke ano o ka hemahema. ʻO kahi papahana e hoʻokuʻu i ka mākaʻikaʻi ala a hoʻopili i ka pōʻaiapuni SPPS like i kahi kaʻina hydrophobic 40-koena e like me kahi peptide maʻamau 15-koena e hana i kahi ʻike haumia i hoʻomalu ʻia e nā ʻoki ʻoki a me nā mea hoʻopau holoi.. Ua like ke ano o keia mau ano me ke ka'ina i ho'opa'a 'ia a hui pū ma lalo o nā kūlana gradient ma'amau. He pipiʻi ka hoʻomohala ʻana i ke ʻano hana hoʻihoʻi hou ma ia pae a hoʻopaneʻe i ka laina manawa i lalo i nā pule.

Haʻawina 2: Pono ka hoʻomohala ʻana o ke ʻano wikiwiki i ka ʻikepili Platform, ʻAʻole nā ​​ʻano hoʻohālikelike o kēlā me kēia kaʻina

No ke aha ia mea. ʻO kekahi o nā paʻakikī no ka hana ʻana i ka lāʻau lapaʻau mRNA pilikino ʻo kēlā me kēia mea maʻi e koi ai i kāna iho hoʻokuʻu hoʻāʻo.. E like me ka ʻO nā lāʻau lapaʻau MDPI 2022 hōʻike hoʻomohala ma ka FRAME-001 lāʻau lapaʻau neoantigen palapala ʻia, ʻO kēlā me kēia ʻāpana peptide synthesized makemake i ka hoʻāʻo waena (helehelena, wahi % ka maemae, ʻike ʻia e UPLC-MS) a hoʻokuʻu hoʻāʻo (ka maemae, ʻike ʻike, endotoxin, sterility) ma mua o ka hoʻokumu ʻana i ka wai. Ke holo nei i ka pōʻaiapili hana maʻamau no kēlā me kēia 20 ʻAʻole hiki ke hoʻokō ʻia nā peptides i kēlā me kēia maʻi ma ka pae lapaʻau; ʻO ka hoʻonā ʻana, ʻo ia nā ala paepae e pili ana i nā kaʻina me ka ʻole o ka hōʻoia hou ʻana.

Hoʻoponopono ka loiloi like i ka ʻike ʻana i ka peptide a me nā papahana CMC me nā ʻano hoʻololi kiʻekiʻe. ʻEkolu mau waiwai o ke ʻano analytical platform: uhi ia i ka laula lehulehu i manaʻo ʻia a me ka laulā hydrophobicity o ka papa kaʻina, hoʻokaʻawale ia i nā papa hana o nā haumia pili kaʻina hana mai ka piko nui ma lalo o kahi kūlana gradient hoʻokahi, a hoʻopuka ia i kahi moʻolelo chromatographic hiki ke hana hou ʻia ma nā ʻāpana a me nā mea loiloi me ka ʻole o ka calibration kikoʻī..

Pehea e hoʻokō ai. Ka liʻiliʻi liʻiliʻi viable analytical pūʻolo no ka liʻiliʻi-puʻe, nā polokalamu hoʻololi kiʻekiʻe:

  • RP-HPLC a i ʻole UPLC hana maʻemaʻe: C18 kolamu ākea-pore (300 Å nui pore, 5 ʻāpana µm a i ʻole sub-2 µm no UPLC), gradient laina mai 5% i 60% acetonitrile i loko 0.1% TFA ma luna o 20-30 minuke, ʻIke UV ma 214 nm. ʻIke ʻia ma 214 Lawe ʻo nm i ka hoʻopaʻa ʻana o ka amide bond o nā iwi kuamoʻo peptide āpau a ʻo ia ka lōʻihi hawewe kuhikuhi no ka helu maʻemaʻe ʻāpana-pakeneka kūpono i nā kaʻina me nā koena ʻala..

  • ʻO ke ʻano ʻike LC-MS: Electrospray ionization (ESI), ʻano maikaʻi, ʻike ʻia ka hōʻike ʻana i ka monoisotopic a i ʻole ka awelika nuipaʻa kūʻē i ka waiwai theoretical, me ka hapa nui i ʻōlelo ʻia ma nā daltons a i ʻole ppm. Pono e hoʻopaʻa ʻia ke ʻano ionization a me ka calibration maʻamau i ka ʻikepili puʻupuʻu - ʻaʻole wale ka "mass match theoretical."

  • Kaʻina hoʻoili protocol: Ke lawelawe ʻia nā mea kūʻai aku a i ʻole nā ​​lab hoʻāʻo i nā pae like ʻole o kahi papahana, aligning column chemistries, nā māka pae kelepona, a ʻo nā ʻāpana ʻike ma mua o ka hana ʻia ʻana o ka pūʻulu mua e pale aku i nā ʻokoʻa haumia ʻike ʻia mai ka ʻokoʻa o ke ʻano ma mua o ka hoʻololi ʻana o ka huahana.. ʻO ka nā protocols hoʻoili analytical harmonized i wehewehe ʻia i loko o nā papahana peptide CMC lehulehu e hōʻike mau ana i nā ʻano HPLC misaligned ma waena o kahi mea hana API a me kahi CRO bioanalytical e hana i nā holo kikoʻī hou e hoʻohui i nā pule i ka manawa me ka ʻole o ka hoʻoholo ʻana i nā nīnau maikaʻi maoli..

Pehea ke ano o ka hemahema. ʻIke ʻia ma 254 nm a i ole 280 nm—hoʻohana mau ʻia i loko o nā keʻena ʻoihana no ka nānā ʻana i ka UV maʻamau—e nele loa i nā mea ʻala ʻole. ʻO kahi pūʻulu peptide i hōʻike ʻia he ≥95% maʻemaʻe ma 280 hiki i ka nm ke hōʻike i kahi ʻike haumia ʻokoʻa ma 214 nm inā loaʻa iā ia nā huahana oxidation a i ʻole nā ​​ʻāpana ʻoki ʻia me nā kaulahao ʻaoʻao ʻala. No kēlā me kēia peptide i hāʻawi ʻia ma ke ʻano he reagent mea hana ola a i ʻole ke kikowaena waena, ʻAʻole kēia he koho calibration - he ʻike a me ka maʻemaʻe āpau e pili ana i ka hana hou ʻana o ka hoʻokolohua..

ʻO ka mea a mākou e ʻike ai ma ka hana. I kā mākou papahana peptide pono'ī, ka 214 nm kue 280 ʻAʻole hiki ke hōʻike ʻia ka ʻokoʻa nm ma ke ʻano he helu nui hoʻokahi - hōʻike ʻia ma ke ʻano he kumu. Ke nānā hou mākou i kahi pūʻulu i maʻemaʻe ma lalo o a 280 ka nānā ʻana i ka nm, ka chromatogram ma 214 Hōʻike mau ʻo nm i nā ʻano haʻahaʻa haʻahaʻa ʻaʻole i hoʻopaʻa inoa ʻia nā lōʻihi hawewe ʻala wale nō: nā puʻupuʻu truncation mua, nā poʻohiwi oxidation late-eluting, a me nā ʻaoʻao kiʻekiʻe kiʻekiʻe i hoʻonui ʻia e hōʻailona ana i ka hoʻoneʻe hapa. He liʻiliʻi ka nui o ka ʻāpana i pili i kēia mau ʻano, akā, hoʻololi ko lākou hele ʻana i ke ʻano o kā mākou wehewehe ʻana i ka hailona-a, ʻoi aku ka mea nui, hoʻololi ia i ka hoʻoholo ʻae. ʻO ia ke kumu he maʻalahi kā mākou lula hana: inā ʻaʻohe koena ʻala o ke kaʻina, a i ʻole inā hoʻolālā ka mea kūʻai aku e hoʻohana i ka mea i loko o kahi haʻawina hoʻolālā-hana a i ʻole ke aʻo paʻa, mālama mākou 214 nm e like me ka lōʻihi hawewe hōʻike me ka nānā ʻole i ka a 280 hōʻike ʻo nm scan. ʻO ka haʻawina no kēlā me kēia mea e wehewehe ana i ka ʻikepili peptide ʻaʻole ia he "pololei" hoʻokahi nalu a he "hewa" ʻē aʻe - ʻo ka lōʻihi hawewe ʻike he koho ʻepekema e kūpono i ke kaʻina a me ka hoʻohana ʻana i lalo., ʻaʻole kahi paʻamau lab i hoʻoili ʻia mai kahi kaʻina hana pili ʻole.

Haʻawina 3: Pono ka ho'āʻo ʻike a me ka haumia i Orthogonal a pae

No ke aha ia mea. ʻO ka maʻamau maʻamau o ka analytical quality gap i ka hāʻawi ʻana i ka peptide liʻiliʻi e hoʻohui i ka maʻemaʻe me ka ʻike. Hoʻokumu ka RP-HPLC wahi-pakeneka o ka maʻemaʻe i ka hapa o ka hōʻailona i ʻike ʻia e pili ana i ka piko nui—ʻaʻole ia e hōʻoia ʻo ka piko nui ke kaʻina i manaʻo ʻia.. Hōʻoia ka mass spectrometry i ke kaumaha molekala o ka ion nui-ʻaʻole ia e kāpae i ka hui pū ʻana i nā haumia isobaric a i ʻole nā ​​isomers sequence e kaʻana like i ka nuipa inoa like..

A 2023 ka nānā ʻana i nā kūlana kuhikuhi USP no ka maikaʻi o ka lāʻau peptide synthetic, paʻi ʻia ma ka Journal of Pharmaceutical and Biomedical Analysis, ua maopopo i keia hookaa ana: ʻike ʻike, ka maemae, maʻiʻo, a ʻo ka hoʻopili ʻana i ka haumia he mau pahuhopu analytical kaʻawale e koi ana i nā ʻano hana ʻokoʻa. ʻAʻole e māʻona kekahi i kekahi.

No nā polokalamu pilikino, pili kēia koi orthogonality ma ka pae hailona, ʻaʻole wale ma ka hōʻoia huahana. Lawe kēlā me kēia pūʻulu i kona mōʻaukala synthesis ponoʻī a no laila kona ʻike pilikino ponoʻī. ʻAʻole hiki ke hoʻohui ʻia i ke koena 14 ʻO kahi kaʻina 25-koena e hoʻopuka i kahi analog holoi ʻana e hiki ke kaʻana like i ka manawa paʻa me ka pahuhopu ma lalo o kahi gradient i hoʻopaʻa ʻia no ka peptide lōʻihi piha akā loaʻa kahi nui like ʻole - ʻike ʻole ʻia e ka ʻike UV wale nō..

Pehea e hoʻokō ai. ʻO kahi protocol hoʻāʻo pae i hoʻopaʻa ʻia i ka pōʻino puʻupuʻu:

Papa hoao

I ka manawa e noi ai

Pūʻolo analytical core

Pākuʻi hoʻokuʻu wikiwiki

ʻO ka hapa mua o kahi mea hou ʻO nā Peptides Synthetic kaʻina maʻamau

RP-HPLC maemae (214 nm, me ka chromatogram) + ʻIkepili LC-MS (ʻōlelo ʻia ka hewa nui, ppm)

Pono ka hailona maʻamau

Hoʻonohonoho hou i kahi kaʻina i ʻike ʻia

RP-HPLC maemae vs. chromatogram kuhikuhi paʻa + LC-MS hōʻoia ʻike

Hōʻike hoʻonui

Nā kaʻina paʻakikī: >30 AA, mau hoʻololi, ala hou

Nā kūlana RP-HPLC Orthogonal + LC-MS/MS ʻāpana ʻāpana + AAA no ka haku mele

Hoʻohana hana a lapaʻau paha

Ka hoʻāʻo ma ke kelepona, haʻawina holoholona, huahana lāʻau i hoʻokumu ʻia

ʻO ka pae piha ma luna + endotoxin (LAL ala), kaumaha olaola, koena solvent, mea kūʻē

No ka hoʻopili ʻana i ka haumia, ʻO nā papa hana haumia i loaʻa mai i ka SPPS e nānā: nā kaʻina i ʻoki ʻia (ka holoi ʻana i hoʻokahi a ʻoi aku paha koena, e kū ana ma ka kuhikuhi C-terminal); huahana hoʻohāhā (Met, Trp, a me Cys ma ke ano he mau kahua kumu, ʻoi aku ka lōʻihi ma hope o ka lawelawe ʻana); ʻano hoʻopau hoʻopau ʻole (ʻO ka hoʻomau Pbf ma Arg ka mea maʻamau ma lalo o nā kūlana cleavage pōkole); a me ka hoʻokomo ʻana i nā analogs mai ka racemization i nā koena i hoʻāla ʻia i ka wā o ka hui ʻana. Hiki iā LC-MS/MS ke hoʻokaʻawale i ka hapa nui o kēia mau papa ma ke ʻano ʻāpana, akā ʻo ka mea i koi mua ʻia he ala RP-HPLC baseline e hoʻokaʻawale iā lākou mai ka piko nui ma mua o ka hoʻohui ʻana iā lākou i kahi ʻāpana ākea hoʻokahi..

⚠️ Hoʻokaʻawale koʻikoʻi: "ʻO ka maʻemaʻe ≥95% e HPLC" a me ka "ʻike i hoʻopaʻa ʻia e MS" ʻelua mau ʻīpuka maikaʻi ʻokoʻa - ʻaʻole e māʻona kekahi i kekahi.. No kekahi peptide lot e komo ana i ka biological assay a i hāʻawi ʻia ma ke ʻano he mea hana, koi ʻia nā mea ʻelua. Hōʻike ʻia nā ʻōkuhi no ka mea e pono ai ka moʻolelo palapala analytical piha i ka hana ka hoʻomaikaʻi ʻana i ka palapala maikaʻi i ka mākeke peptide noiʻi, kahi i ʻike ʻia ai ka ʻāpana hoʻopihapiha hoʻopaʻa ʻana like me kahi manaʻo maikaʻi ʻōnaehana.

ʻO ka ʻO ka palapala protocol hoʻāʻo ʻike ʻike AxonVerified (2026) haʻi pololei i ka loina hana: Hōʻike kēia ʻano hana ʻelua i ka maʻamau i hoʻohana ʻia i ka hoʻāʻo ʻana i ka lāʻau lapaʻau i hoʻopaʻa ʻia - ʻo ka helu maʻemaʻe e hoʻokumu i ka nui o ka hāpana ʻo ka pūhui pahuhopu., ʻoiai ʻo ka hōʻoia ʻike e hoʻokumu i ke ʻano o ia hui. E pili ana

Haʻawina 4: Pono ka Palapala Hoʻopaʻa liʻiliʻi i kahi kumu hoʻohālike i kūkulu ʻia

No ke aha ia mea. Nā ʻano hoʻopaʻa moʻolelo puʻupuʻu maʻamau i hoʻolālā ʻia no ka nui, ʻAʻole hoʻokō ka hana peptide hoʻokahi i ka wikiwiki o ka hana a i ʻole ka hoʻololi ʻana o nā papahana kiʻekiʻe.. He loiloi i paʻi ʻia e PolyPeptide ma neoantigen peptide hana hana hai pololei: ʻAʻole ʻae nā moʻolelo batch maʻamau i hoʻohana ʻia i ka hana peptide kuʻuna i ka maʻalahi a me ka wikiwiki e pono ai no ka hana peptide neoantigen., a pono e hoʻomohala a hoʻohana ʻia kahi palapala hōʻike pūʻulu GMP maʻalahi akā piha. Hana ʻia ʻo Peptide

Pili ka hopena like i kēlā me kēia puʻupuʻu liʻiliʻi, ʻO ka polokalamu peptide kiʻekiʻe e holo ana ma lalo o nā manawa i hoʻopaʻa ʻia - inā he wai peptide neoantigen no kahi keʻena immunology hoʻonaʻauao., he panel maʻamau i loko i kapa ʻia ka isotope maʻamau no kahi hōʻike PK/PD, a i ʻole he pūʻulu o nā analogs i hoʻololi ʻia e loiloi ʻia i nā haʻawina SAR like.

Pehea e hoʻokō ai. ʻO kahi pūʻolo palapala kūpono no nā papahana peptide liʻiliʻi he ʻeono mau mea traceability:

  1. Hoʻopaʻa moʻolelo: ʻO ke kaʻina amino acid piha, nā kūlana hoʻololi, hoʻolālā hui pale, a me ka hoʻonohonoho ala (SPSS, huikau, etc.). Pono e hoʻokomo i kahi hōʻailona maʻemaʻe maʻemaʻe ma mua o ka hoʻokō ʻana o ka hui i ka hoʻomaʻemaʻe, no laila ua hōʻailona ʻia nā ʻāpana palena ma mua o ke koi ʻia.

  2. mooolelo analytical lot-specific: RP-HPLC chromatogram makaʻala (paʻa ʻole, me ka hōʻike hoʻohui ma 214 nm), LC-MS piha kikoo (nuipa theoretical, nuipa i nānā ʻia, ʻano hoʻokaʻawale, mea kani, maʻamau calibration), a ma kahi e pili ai, AAA a i ʻole nā ​​hōʻoia orthogonal ʻē aʻe. Pono e mālama ʻia nā faila ʻikepili maka—ʻaʻole wale ka papa hōʻuluʻulu manaʻo.

  3. Palapala ʻike kaulahao: No nā papahana kahi i loaʻa mai ai ke kaʻina peptide mai kahi kumu olaola kikoʻī (biopsy ma'i, kelepona ʻokoʻa, ʻO ka hana genotype HLA), Pono ke ala palapala e hoʻopili i ka mea ʻike kumu i ka kikoʻī synthesis i ka helu hailona i ka moʻolelo hoʻokuʻu. ʻO kēia ka peptide-ʻaoʻao like o ke kaulahao-o-ʻike pono i nā papahana hana mRNA a hiki ke loiloi ʻia ma lalo o nā loina ʻōnaehana maikaʻi o ICH Q10..

  4. Hoʻokuʻu papa kuhikuhi: Nā pae hoʻohālike ʻae ʻia no kēlā me kēia ʻano i hoʻāʻo ʻia, ʻōlelo ʻia ma ka helu. “Maemae: ≥95.0% e RP-HPLC wahi ma 214 nm" he kiko'ī. ʻAʻole "maʻemaʻe kiʻekiʻe".. ʻO ka EMA Alakaʻi no ka hoʻomohala ʻana a me ka hana ʻana o nā Peptides Synthetic pono e hoʻonoho ʻia nā palena maʻemaʻe a me ka haumia me nā ʻano analytical wehewehe a me nā paepae kūpono. Pono e mālama ʻia kēlā kūlana ma ke ʻano he papahele, aole he kaupaku, ʻoiai ma ka hana pre-IND.

  5. Kuhikuhi hailona comparability heleuma: ʻOiai ma nā papahana noiʻi, ʻo ka mālama ʻana i hoʻokahi pūʻulu i hōʻike ʻia i kēlā me kēia kaʻina e hiki ai ke loiloi ʻia nā hailona e hiki mai ana i kahi papa kuhikuhi.. He hana haʻahaʻa haʻahaʻa kēia me ka waiwai nui o lalo i ka wā e kū mai ai nā nīnau ikaika o ke ʻano a i ʻole ke hoʻololi ʻana o ka mea kūʻai aku e pono ai ka hōʻike hoʻohālikelike.. A peptide IND CMC papa inoa i hoʻomohala ʻia no nā papahana IND-stage e hāʻawi i kahi laʻana kūpono no ka hoʻonui ʻana i nā koi palapala i ka wā e holomua ai ka pae hoʻomohala.

  6. ʻO ka hoʻopaʻa ʻana a me ka piʻi ʻana: He kahua e ʻike ana i ka hoʻokaʻawale ʻana o ka synthesis — ʻike ʻia ka hemahema o ka hui ʻana e ka ninhydrin a i ʻole ka nānā ʻana o UV., hoʻololi resin i waena o ka synthesis, hoʻololi gradient i ka wā hoʻomaʻemaʻe—a me ka pane i lawe ʻia. No nā polokalamu e hoʻohana ana i nā CDMO waho a i ʻole nā ​​mea kūʻai aku he nui, ʻO kēia moʻolelo ke ʻano e ʻike ʻia ai ka neʻe ʻana o ke kaʻina hana ma mua o ka lilo ʻana i mea maikaʻi ʻole.

Pehea ke ano o ka hemahema. ʻO kahi papahana e hāʻawi ana i nā peptide lot me ka ʻikepili CoA i kaupalena ʻia i ka waiwai maʻemaʻe HPLC hoʻokahi a me ka hōʻoia nui o ka inoa ʻaʻohe mea hana no ka ʻike ʻana i ka neʻe ʻana o ka lot-to-lot i loko o ka ʻike haumia., ʻaʻohe kumu no nā koi hoʻohālikelike, a ʻaʻohe ʻōnaehana maikaʻi e pale ʻia inā hoʻi ka hemahema o ka assay i ka mea peptide. Ma nā papahana hoʻonaʻauao, ʻike pinepine ʻia kēia ma ke ʻano he ʻikepili pane-pane hiki ʻole ke hoʻopili ʻia i ka ʻokoʻa olaola. I nā papahana biopharma, ʻike ʻia ma nā ʻano ʻawaʻawa a i ʻole nā ​​leka IND me ka ʻoihana.

Pehea ke ano o ka hemahema. ʻO kahi papahana e hāʻawi ana i nā peptide lot me ka ʻikepili CoA i kaupalena ʻia i ka waiwai maʻemaʻe HPLC hoʻokahi a me ka hōʻoia nui o ka inoa ʻaʻohe mea hana no ka ʻike ʻana i ka neʻe ʻana o ka lot-to-lot i loko o ka ʻike haumia., ʻaʻohe kumu no nā koi hoʻohālikelike, a ʻaʻohe ʻōnaehana maikaʻi e pale ʻia inā hoʻi ka hemahema o ka assay i ka mea peptide. Ma nā papahana hoʻonaʻauao, ʻike pinepine ʻia kēia ma ke ʻano he ʻikepili pane-pane hiki ʻole ke hoʻopili ʻia i ka ʻokoʻa olaola. I nā papahana biopharma, ʻike ʻia ma nā ʻano ʻawaʻawa a i ʻole nā ​​leka IND me ka ʻoihana.

ʻO kā mākou mea kūʻai e haʻi mai iā mākou. ʻO nā nīnau a mākou e lohe pinepine ai mai nā pūʻulu noiʻi ʻaʻole loa e pili ana i ka synthesis - pili lākou i nā palapala. ʻElua hoʻi hou me ke ʻano kūlike. ʻO ka mua he mana o "ka palapala hōʻoia 98% maemae, akā ʻo ia ka peptide kūpono?”—ka ʻike, hiki mai ma hope o ka hopena ho'ā'o pohihihi, ʻaʻole i hoʻokumu ʻia kahi kiʻi maʻemaʻe wale nō. ʻO ka lua he nīnau hoʻohālikelike: "Ua hoʻonohonoho hou mākou i ke kaʻina like ʻeono mahina ma hope a loaʻa kahi hopena ʻē aʻe - ua loli ka huahana, a i ʻole ka hoʻāʻo ʻana?” Ma na hihia elua, like ka pono kumu: he ala palapala e hoʻohui i ke kaʻina, ka ʻikepili maka, nā pae hoʻokuʻu, a me kekahi kuhi hewa i loaa ma ke ala. No ka mea, ke kūkulu nei mākou i kahi moʻolelo kiʻekiʻe loa no kēlā me kēia kaʻina hana - me nā faila RP-HPLC a me LC-MS maka., ʻaʻole wale ka laina hōʻuluʻulu—hiki ke pane ʻia kēia mau nīnau mai ka waihona pūʻulu ma mua o ka hoʻohui hou ʻana a me ka hoʻāʻo hou ʻana.. ʻO ia ka waiwai kūpono o nā palapala kūpono no ka hana: hoʻololi ia i ka hopohopo o ka mea kūʻai aku i mea maʻamau, pane loiloi.

Hoʻohui i nā haʻawina mRNA i ka hoʻolālā holo kaʻina hana peptide: He Hōʻuluʻulu Manaʻo

Hōʻike ka papa ma lalo i nā haʻawina hana ʻehā mai nā papahana kano mRNA pilikino i kā lākou hana like i ka peptide analytics a me ka hoʻomaʻamaʻa CMC..

ka pilikia hana mRNA

ʻO ka hoʻokūkū peptide parallel

Hana hoʻomalu

ʻAʻole hiki i nā pūʻulu n-of-1 ke hahai i kahi kaʻina monolithic

Pono ka hoʻololi ʻana o ke kaʻina kiʻekiʻe i nā ala synthesis hiki ke hoʻonohonoho hou ʻia

Papahana modular: mākaʻikaʻi ala me nā mea hoʻoholo hoʻoholo i wehewehe ʻia, ʻāpana-hana-level ʻae ʻae

Pono kēlā me kēia ʻāpana maʻi i kāna pōʻai hoʻāʻo ponoʻī

Loaʻa i kēlā me kēia ʻano kaʻina kaʻina i kahi ʻano ʻokoʻa pilikia o ka haumia

Nā ʻano analytical platform (RP-HPLC maʻamau + LC-MS) e uhi ana i ka papa kaʻina piha

ʻO ka maʻemaʻe a me ka ʻike he mau puka hoʻokuʻu kaʻawale

Maʻemaʻe HPLC ≠ ʻike MS; koi ʻia nā mea ʻelua i ka hailona

ʻO ka hoʻāʻo Orthogonal: RP-HPLC ma 214 nm + ESI-MS me ka hapa nui i hōʻike ʻia

Pono e hoʻopaʻa ʻia ke kaulahao mai ka biopsy a hiki i ka hoʻokuʻu ʻana

Pono ka ʻike kumu-a-lot no nā kaʻina i loaʻa mai i ka biologically

Nā moʻolelo pūʻulu i kūkulu ʻia me ʻeono mau mea traceability me ka mālama ʻana i ka ʻikepili maka

Paʻa loa nā moʻolelo pūʻulu GMP maʻamau no nā kaʻina manawa pilikino

ʻAʻole i hoʻolālā ʻia nā moʻolelo synthesis maʻamau no ka pōkole, nā polokalamu hoʻololi kiʻekiʻe

Nā palapala palapala maʻalahi akā hoʻopiha piha, pae-kūpono

ʻAʻole kēia hoʻohālikelike he hoʻopaʻapaʻa no ka hoʻohana ʻana i nā mana GMP clinical i nā peptides noiʻi mua. He paio no ka hoohana ana i ka hale hoʻolālā o ia mau mana—modular production thinking, ʻānai ʻana i ka orthogonal, nā palapala i hoʻopaʻa ʻia—ma ke ʻano o ke koʻikoʻi kūpono i ka papahana. Hoʻokuʻu pinepine nā papahana noiʻi i kēia mau mana ʻaʻole no ka mea ʻaʻole pili ka loina kumu, akā, no ka mea, ʻaʻohe mea nāna i unuhi i ka framework i nā mea paʻa pono no ka pōʻaiapili non-GMP.

He aha kāu e hana ai inā ʻoi aku kāu polokalamu ma mua o ʻelima mau kaʻina

Inā hoʻopuka kāu polokalamu i kēia manawa i nā pūʻulu ma waena o ʻelima mau kaʻina like ʻole, a i ʻole ka holomua ʻana i nā mea e pili ana i nā hoʻokolohua hana a me nā noiʻi holoholona, ʻekolu mau manaʻo hoʻoholo kaʻina hana e hoʻoholo i ka hapa nui o ka pilikia o ka maikaʻi o lalo:

E kuhikuhi i ke ala ma mua o ka hana ʻana: Ke hoʻohana nei kāu hui a i ʻole CDMO i kahi protocol scouting i kūkulu ʻia me nā mea hoʻoholo hoʻoholo, a i ʻole ke koho ʻana i ke ala e hoʻoholo ʻia e ka mea kūʻai aku a me ke ʻano hoʻohālikelike i nā molekala mua?

Hoʻopiha hoʻopaʻa ʻana: Loaʻa i kēlā me kēia hailona i hoʻokuʻu ʻia ka ʻikepili maʻemaʻe RP-HPLC i ʻike ʻia ma 214 nm (me ka chromatogram maka), Hōʻike ʻia ka ʻikepili ʻike ESI-MS me ka hapa nui, a me ka paʻa ʻana o nā faila mea hana maka—a i ʻole he papa hōʻuluʻulu wale nō?

Hiki ke hoʻopaʻa palapala: Hiki ke ʻike ʻia kahi anomaly maikaʻi ma kahi hoʻāʻo i ka moʻolelo puʻupuʻu, ka log deviation synthesis, a me ka ʻikepili ʻikepili maka mua ma lalo 30 minuke?

ʻO ka MOL Changes Hoʻopuka ka platform peptide synthesis maʻamau i nā pūʻolo palapala pae nui e uhi ana i nā chromatograms RP-HPLC, kiʻekiʻe ESI-MS spectra, a me ka hōʻoia hōʻoia ʻike hewa nui no kēlā me kēia kaʻina hana - e hoʻohana ana i ka hoʻokolohua hoʻāʻo orthogonal like i wehewehe ʻia ma kēia ʻatikala i nā kaʻina papa inoa maʻamau a me nā hoʻololi maʻamau paʻakikī.. Hiki i nā hui ke kūkulu a hōʻailona paha i kā lākou peptide workflows e kū'ē i kēia anga ke noi i kahi loiloi kūpono ʻenehana e uhi ana i ke koho ala synthesis., hoʻolālā hoʻomalu haumia, a me ka hoʻolālā papapalapala palapala no nā papahana hoʻololi kiʻekiʻe.

Zejun Peng

Zejun Peng

Luna ʻenehana Nui; ʻO ka mea akamai i ka peptide Synthesis Kaʻike kumu: ʻO ka peptide synthesis paʻakikī, nā hoʻololi ʻana o ka amino acid kūlohelohe, a me ke kūkulu ʻana i nā peptides cyclic a me nā peptides stapled.

moʻokalaleo:He ʻike nui ʻo Zejun Peng i ka kemika kūlohelohe a me ka synthesis peptide. Maikaʻi ʻo ia i ka hoʻohana ʻana o ka solid-phase peptide synthesis (SPSS) a me ka peptide synthesis wai (LPPS), a akamai loa i ka lanakila ʻana i nā "paʻakikī loa-e-synthesize sequences" (e like me nā peptides ultra-long-chain, nā kaʻina hydrophobic kiʻekiʻe, a me ka pelu ana i na mea paa disulfide lehulehu). Ma lalo o kāna alakaʻi, ua lanakila ka hui i nā bottlenecks ʻenehana i kekahi mau hoʻololi kūikawā (e like me ka N-methylation, PEGylation, a me ka lepili fluorescent), ka mālama ʻana i ka helu kūleʻa synthesis o luna 98%.

ʻIke ʻia & Nā alakaʻi hoʻoponopono
Nānā ʻia e: Ka poe akamai kumuhana
Kaʻana like i kēia ʻatikala
Home Huli Whatsapp Nā lawelawe Huahana